China Investigates Fatal Gene Editing Experiment

Shanghai Jiaotong University School of Medicine is investigating a fatal experimental gene-editing trial conducted at Xinhua Hospital last year. The case involves a young girl whose parents paid $860,000 for a treatment aimed at correcting a gene defect behind developmental delays.

The hospital's ethics board concluded the girl's death was directly related to the treatment. However, the outcome was not publicly disclosed, even as related research was published in the journal Nature. This incident has reignited ethical concerns in China's rapidly expanding biomedical sector, drawing parallels to a previous gene-editing embryo scandal.

The clinical trial was an investigator-initiated trial, a type of research that may undergo less oversight. Despite assurances of safety from the lead researcher, the girl developed severe symptoms shortly after treatment and died. The hospital was later fined for failing to properly oversee the trial.

In response to the controversy, Nature is investigating concerns about the published research, which did not mention the human trial or the child's death. New regulations were recently rolled out in China to strengthen oversight of advanced therapies, aiming to balance innovation with patient safety.